Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA on Phase IV trials

This article was originally published in The Tan Sheet

Executive Summary

The design and implementation of post-marketing commitments will be studied by an outside contractor as part of a new FDA initiative to evaluate and improve the Phase IV commitment process, according to Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb, MD. The intiative will "evaluate and perhaps improve how we use post-marketing commitments," Gottlieb said during an American Enterprise Institute discussion Feb. 8 in Washington, D.C. The agency currently is in negotiations and expects to announce the contract for the one-year study in the next few weeks. "The objectives of this effort are to evaluate the consistencies of the processes within the divisions, across divisions within FDA and also across different medical centers for requiring, requesting and facilitating as well as reviewing post-market commitments," Gottlieb said...

You may also be interested in...



EU ‘Structured Dialog’ Offers Opportunity To Secure Supply

A “structured dialog” led by the European Commission with pharmaceutical industry stakeholders provides a critical opportunity to address weaknesses in the stability and security of the supply chain by improving the environment for local manufacturing, Medicines for Europe believes.

Adcock Struggles As South African Healthcare Awaits Relief

Despite a slight increase in revenue, South Africa’s Adcock continues to struggle as it reports a continued drop in gross profit. The company expects the economy to remained constrained due to COVID-19, but is eagerly anticipating recovery with the government’s vaccine roll-out.

EMEA Round-Up: Bayer Strikes Egypt Deals, Orkla Acquires NutraQ, Uriach Grabs Sidroga

Round-up of the latest news across EMEA, including two deals for Bayer in Egypt and Saudi Arabia; Orkla's acquisition of NutraQ; and Uriach's deal for Sidroga.

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel